Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 2-year results from the Japan subgroup of the phase III TENAYA trial

Purpose To evaluate 2-year efficacy, durability, and safety of faricimab in the TENAYA Japan subgroup and pooled global TENAYA/LUCERNE cohort of patients with neovascular age-related macular degeneration (nAMD). Methods Subgroup analysis of TENAYA/LUCERNE (NCT03823287/NCT03823300): phase III, multic...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Graefe's archive for clinical and experimental ophthalmology 2024-08, Vol.262 (8), p.2439-2448
Hauptverfasser:	Koizumi, Hideki, Gomi, Fumi, Tsujikawa, Akitaka, Honda, Shigeru, Mori, Ryusaburo, Ochi, Haruka, Iwasaki, Keisuke, Okada, Annabelle Ayame
Format:	Artikel
Sprache:	eng
Schlagworte:	Acuity Age Aged Angiogenesis Inhibitors - administration & dosage Angiogenesis Inhibitors - adverse effects Clinical trials Dose-Response Relationship, Drug Double-Blind Method Drug Administration Schedule Female Fluorescein Angiography Follow-Up Studies Humans Intravitreal Injections Japan - epidemiology Macular degeneration Male Medicine Medicine & Public Health Middle Aged Monoclonal antibodies Ophthalmology Receptors, Vascular Endothelial Growth Factor - administration & dosage Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors Recombinant Fusion Proteins - administration & dosage Retinal Disorders Time Factors Tomography, Optical Coherence Treatment Outcome Vascular Endothelial Growth Factor A - antagonists & inhibitors Vision Visual Acuity Wet Macular Degeneration - diagnosis Wet Macular Degeneration - drug therapy Wet Macular Degeneration - physiopathology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!